ClinicalTrials.gg
Active, not recruitingNCT06512584Updated Oct 22, 2026

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

A Phase 3 interventional study of PJ009 and PJ009 Placebo in Short Bowel Syndrome, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Active, not recruiting at 8 sites in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Short Bowel Syndrome with a site in China — 4 open to participants now, 6 under way, 2 of them phase 3. Short Bowel Syndrome · China.

Planned enrollment
3rd of 10
72 · median 27
Started
2024
with 1 other
Phase 3
2 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
3 of 12
Chongqing Peg-Bio Biopharm Co., Ltd.

Among the 12 studies in Short Bowel Syndrome with a site in China, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 3, and was the 5th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

4 of the 12 studies in Short Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Short Bowel Syndrome with a site in China, or all of them as a file.
02

Study summary

The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are:

  • How effective is PJ009 in treating short bowel syndrome?
  • Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS.

Participants will

  • Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks,
  • Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment,
  • Keep a diary of the amount of their parenteral nutrition/ intravenous fluids (PN/IV), enteral nutrition and urine volume.
Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled clinical study, aiming to evaluate the efficacy, safety, immunogenicity and pharmacokinetic of PJ009 in patients with short bowel syndrome requiring parenteral nutrition, using placebo as a control.

The trial is divided into 3 periods. Period 1 of this trial is the screening, optimization (if applicable, up to 8 weeks) and stabilization (4-8 weeks) period. At the end of the stabilization period, a baseline enrollment evaluation will be performed, and all eligible participants will enter the 24 weeks of double-blind treatment period (period 2). Period 3 is a 12-week open label extension to period 2. Safety follow-up assessments will be performed 4 weeks after the last dose in treatment period 3.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Short Bowel Syndrome
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female aged ≥ 14 years;
  2. SBS patients dependent on PN/IV support for at least 6 consecutive months due to major intestinal resection;
  3. At least 3 PN/IV support sessions per week are required 1 week before screening or 2 weeks before baseline;
  4. Be on stable PN/IV support for at least 4 consecutive weeks before administration;
  5. For subjects with a history of Crohn's disease (CD), clinical assessment of remission for at least 12 weeks prior to administration;
  6. Be able to understand and provide signed , for those under 18 years old, the guardian should also sign the informed consent;
  7. Be able to complete experiments in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have used teduglutide in the past or may be allergic to teduglutide or its components;
  2. Have used natural GLP-2 or its analogs, human growth hormone or its analogs within 6 months before screening;
  3. Have used glutamine, octreotide, GLP-1 analogs or dipeptidyl peptidase-IV inhibitors within 30 days before screening;
  4. With active Crohn's disease or those who need to change biological therapy within 6 months before screening;
  5. With active inflammatory bowel disease (IBD) or IBD patients who have received therapy changes in the past 3 months;
  6. With unstable absorption due to cystic fibrosis, untreated megacolon disease or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome);
  7. With clinically obvious intestinal obstruction or active stenosis within 6 months before screening;
  8. Have undergone major gastrointestinal surgical intervention within 3 months before screening, such as continuous transverse enteroplasty or other intestinal lengthening surgery (esophageal intubation or endoscopic surgery is allowed);
  9. Severe active, uncontrolled, untreated systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system diseases, etc.);
  10. Have malignant tumors within 5 years before screening (except for fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery);
  11. With severe liver function impairment:

    1. Total ≥ 2.0 × (ULN); for patients with Gilbert's syndrome, direct bilirubin ≥ 2.0 × ULN;
    2. (AST) ≥ 5.0 × ULN, alanine transaminase (ALT) ≥5.0 × ULN;
  12. With renal function impairment:

    1. Serum creatinine ≥2.0 × ULN;
    2. \< 60 ml/min (calculated according to the Cockcroft-Gault formula, see Appendix 3 for details);
  13. Pancreatic abnormalities:

    1. Serum amylase ≥ 2.0 × ULN;
    2. Serum lipase ≥ 2.0 × ULN;
  14. More than 4 SBS or PN-related hospitalizations (such as catheter sepsis, intestinal obstruction, severe water and electrolyte disorders) within 12 months before screening;
  15. Unplanned hospitalization within 30 days before screening;
  16. Pregnant or lactating women, women or men who have fertility plans or do not agree to take effective measures during the trial;
  17. Participated in any clinical trial (excluding antibody treatment-related clinical trials) within 30 days before screening or participated in any antibody treatment-related clinical trials within 3 months before screening;
  18. Other condition the investigator believes would be unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    PJ009

    subcutaneous injections, 0.05 mg/kg once daily

    Drug: PJ009

  • Placebo comparator
    PJ009 Placebo

    subcutaneous injections, once daily

    Drug: PJ009 Placebo

Interventions

  • DrugPJ009

    subcutaneous injections, 0.05 mg/kg once daily

    Also known as: Glucagon-Like Peptide 2 (GLP-2) analogue

  • DrugPJ009 Placebo

    subcutaneous injections, once daily

    Also known as: GLP-2 analogue Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of responders

    A responder's PN/IV volume per week shows a reduction of at least 20% from baseline from week 20 to 24 in treatment period.

    Time frame: Week 20 to 24 of treatment period

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Sep 2026, 24 months.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 24 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2026 → Sep 2026 and completion Apr 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 22, 2024
StartActual
Sep 3, 2024
Primary completionActual
Sep 28, 2026was Mar 2026
CompletionEst.
Mar 15, 2027was Apr 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 22, 2026
Primary completion
Mar 30, 2026→Sep 28, 2026 (actual)
Oct 22, 2026
Study completion
Apr 27, 2026→Mar 15, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 30, 2026→Sep 28, 2026 (now actual)
    Study completion Apr 27, 2026→Mar 15, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06512584
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Sep 3, 2024
Primary completion
Sep 28, 2026
Completion
Mar 15, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Huanlong Qin
principal investigator · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion